Introduction
Given the widespread availability of several effective multidisciplinary care plans, the decision-making and clinical management for the patient with head and neck squamous cell carcinoma (HNSCC) are complicated. Although national guidelines like the National Comprehensive Cancer Network (NCCN) guidelines in the United States exist for patient care by disease site and stage of disease [1] , the choice of therapeutic approach for a particular patient should be based on goals of care, patient functional status and comorbidities, and morbidities 1 3 radiotherapy improves clinical outcomes-organ preservation rates, locoregional disease control, and survival-as compared to radiotherapy alone. However, given the potential for enhanced toxicity, overtreatment, and inefficient use of healthcare resources, the selection of patients who can benefit from systemic therapy is critical. In this editorial, we briefly review the nonstandard uses of this important treatment modality and identify patient populations for whom such therapy may be challenging, with the goals of guiding high-quality, individualized, and evidence-based treatment plans for HNSCC patients and of highlighting specific areas requiring attention for the design of future clinical trials.
Nonstandard/investigational applications of systemic therapy
In the following clinical situations, there is inadequate data to support clinical benefit from the use of systemic therapies, and their application is therefore investigational.
Early/intermediate stage disease

Systemic therapy should not be administered concurrently with radiotherapy for early or intermediate stage HNSCC
Concurrent chemoradiotherapy (or in the case of use of cetuximab, bioradiotherapy) is a recommended treatment option for patients with locoregionally advanced (stages III and IV) HNSCC. With the exception of stage II nasopharyngeal cancers for which chemoradiotherapy is currently considered standard [1] , the use of chemoradiotherapy or bioradiotherapy for earlier stages of disease (i.e., stages I and II, lymph node negative) is not recommended outside of clinical trials due to the generally excellent outcomes with either surgery or radiotherapy alone.
Altered radiotherapy fractionation regimens
Systemic therapy should not be administered concurrently with altered radiotherapy fractionation regimens
Despite known survival benefits of treating locoregionally advanced HNSCC with either concurrent chemoradiotherapy or altered fractionated radiotherapy regimens over standard radiotherapy fractionation alone [2] [3] [4] , efforts to further intensify therapy by the addition of chemotherapy to accelerated radiotherapy plans have failed to improve on clinical outcomes over conventional chemoradiotherapy in recently published randomized phase III trials (RTOG 0129 and GORTEC 99-02) [5, 6] . With hopes to further improve outcomes, the Radiation Therapy Oncology Group (RTOG) is currently using mildly accelerated radiation (6 fractions per week as in the DAHANCA 6 & 7 trial [7] and the IAEA-ACC trial [8] ) with concurrent chemotherapy as the standard arm in its trials. However, outside of a clinical trial, chemotherapy should be administered concurrently with conventionally fractionated radiotherapy [9] .
Adjuvant or maintenance therapy
Systemic therapy should not be used as an adjuvant or maintenance therapy for non-nasopharyngeal HNSCC
The study of cytotoxic agents following radiotherapy or chemoradiotherapy for HNSCC has been hampered due to poor patient tolerance. The use of novel biological agents that can be administered orally or enterally may have greater promise in this regard, and several clinical trials of this approach are ongoing or in development. For nasopharyngeal cancer, adjuvant chemotherapy may not be essential for improving overall survival [10] , but studies of Epstein-Barr viral load offer a rational approach for selective treatment of high-risk patients.
Chemotherapy alone with curative intent
Do not use systemic therapy as a single modality for HNSCC when the treatment goal is cure
A few recent studies of chemotherapy as a single treatment modality have demonstrated proof of concept of long-term patient survival and disease control in very highly selected patients with laryngeal cancer [11] [12] [13] . However, this highly novel approach remains experimental and should not be performed outside of a clinical trial [14, 15] .
Intra-arterial (IA) chemotherapy
IA chemotherapy, despite demonstrated feasibility and efficacy in multi-institutional settings, is not superior to intravenous chemoradiotherapy and remains experimental
IA chemotherapy has been evaluated for over 50 years to exploit pharmacokinetics of a number of cytotoxics. More recently studied, high-dose IA cisplatin can be administered locally, while systemic toxicities are reduced by a simultaneous intravenous infusion of sodium thiosulfate [16] . The bulk of the literature shows that IA administration via a femoral catheter is feasible for squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx with acceptable systemic toxicity. Toxicities related to IA therapy include tumor necrosis, bleeding, and, more rarely, cerebrovascular events [17] . Similar to intravenous drug administration, the response to neoadjuvant IA cisplatin may also be predictive of final oncologic outcomes after definitive surgery or radiation therapy [18] . Feasibility and effectiveness of concomitant IA cisplatin and radiation therapy (RADPLAT) were shown in a prospective multi-institutional study [16] , with complete responses in greater than 80 % of patients. High-dose IA cisplatin with concomitant hyperfractionated radiation therapy has also been shown to be feasible with complete response rates of greater than 85 % for advanced and unresectable tumors [19, 20] .
Despite these initial promising results, the only published randomized phase III trial of IA cisplatin versus concomitant intravenous chemoradiation in patients with locoregionally advanced, (functionally) unresectable HNSCC failed to demonstrate improved oncologic outcomes with IA therapy [21] . The extent of toxicities between the two treatment arms was comparable, though the sites of toxicity differed; notably, serious (grade 3 or 4) nephrotoxicity was more common in the intravenous arm while neurotoxicity was more prevalent in the IA arm. Moreover, recently published 5-year quality of life evaluations from this trial did not detect significant differences between the two approaches [22] . As a result, this mode of therapy remains investigational and should not be performed outside of a clinical trial.
Re-irradiation for recurrent or second primary HNSCC
Particular caution must be exercised when systemic therapy is used in combination with re-irradiation for selected patients
The use of re-irradiation following failure of initial therapy of HNSCC has some limited efficacy. In 2008, the Groupe d'Etude des Tumeurs de la Tête Et du Cou (GETTEC) and Groupe d'Oncologie Radiothérapie Tête Et Cou (GORTEC) reported on the results of a small (N = 130 patients) phase III randomized trial of postoperative re-irradiation combined with chemotherapy compared with salvage surgery alone [23] . Although locoregional control and disease-free survival were improved in the combined chemotherapy and re-irradiation arm, no improvement in overall survival was noted, and the combined regimen was associated with increased severe toxicities and several treatment-related deaths.
In the setting of unresectable locoregionally recurrent or second primary cancers, in view of the morbidities associated with and limited efficacy of re-irradiation, the role of concomitant cytotoxic chemotherapy or biologic therapy is unclear because of lack of randomized data. When systemic therapy is considered, particularly when patients have been previously treated with chemoradiation which appears to be an adverse prognostic factor for survival [24] , combining re-irradiation with cetuximab deserves study. Currently, there is no standard approach for combining chemotherapy with re-irradiation [25] .
Special populations
Systemic therapy is rarely devoid of toxicity, and caution must be exercised in its use. That said, few absolute contraindications exist for the use of systemic cancer therapies, and those that exist are usually specific to the toxicity profiles of the chemotherapeutic agents employed.
Although a full discussion of the toxicities of chemotherapeutic agents is beyond the scope of this editorial, there are several specific clinical scenarios where alterations in therapy or omission of chemotherapy should be considered in the management of HNSCC. It should certainly be appreciated that elderly patients, those with organ dysfunction or poor performance status (PS), as well as those with human immunodeficiency virus (HIV) infection have generally been under-represented from clinical trials; these exclusions weaken our recommendations.
Elderly patients
The recognition of cancer as a disease of aging has led to increased focus on clinical outcomes and tolerability of cancer therapies in patients with advanced age. However, clinical research involving this commonly encountered patient population is limited by few prospective studies and widely variable definitions of "the elderly."
Advanced age at HNSCC diagnosis is not an absolute contraindication for systemic therapies; however, it is one of many variables-including organ function, comorbid burden, polypharmacy, nutritional status, cognitive function, socioeconomic issues, geriatric syndromes, and patient preferences-that must be considered in patient management [26] . Although the MACH-NC showed a modest but significant survival benefit with the addition of chemotherapy to radiotherapy for HNSCC, it did not confirm this benefit in the subset of patients over 70 years of age [2] , highlighting the need for prospective trial data for this population. Cetuximab has often been considered for elderly patients given its generally tolerable toxicity profile and lack of drug-drug interactions; however, survival benefit in patients 65 years and older and those with poor functional status was not demonstrated in subset analyses of the definitive trial led by Bonner et al. [27] .
Patients with organ dysfunction
The use of systemic therapy in patients with organ dysfunction is a frequently encountered clinical challenge. Chemotherapy toxicities may result in exacerbating pre-existing renal dysfunction or hearing loss (e.g., with cisplatin), neuropathy (e.g., with paclitaxel), or bone marrow dysfunction (all cytotoxic agents), and impaired metabolism or clearance of the drug can certainly enhance toxicities. Baseline renal dysfunction may lead to increased toxicity of methotrexate, and hepatic dysfunction increases the toxicity of taxanes. Although cetuximab has been advocated by some for use in patients with pre-existing renal insufficiency or other organ dysfunction, it is not known whether clinical outcomes or toxicities are similar in otherwise fit patients.
Patients with poor functional (performance) status
Careful consideration of regimen tolerability must be weighed in the care of HNSCC patients with impaired functional status. Although disease-associated symptoms can greatly improve with induction chemotherapy approaches for previously untreated disease and serve as a bridge to subsequent chemoradiotherapy [28] , induction chemotherapy has not improved survival [29] [30] [31] and should only be administered in tertiary centers [1] . Moreover, patients with impaired functional status were not included in the prospective studies of induction chemotherapy, and the acute toxicities of this approach and the potential for additional treatment-associated mortality must be recognized [28] .
There have been rare studies that have investigated therapies focused on patients with poor functional status, known to be associated with poor outcomes in patients with incurable HNSCC [32] . The Eastern Cooperative Oncology Group (ECOG) recently reported results of a randomized, placebo-controlled, phase III clinical trial of weekly docetaxel with or without gefitinib for patients with unresectable recurrent and/or metastatic HNSCC specifically with an ECOG PS of 2 (ECOG 1302) [33] . The study accrued 270 patients before closure at interim analysis. The median overall survival of patients treated with docetaxel was only 6.0 months, which was not improved with the addition of gefitinib (median overall survival = 7.3 months; hazard ratio 0.93; 95 % confidence interval 0.72 to 1.21; P = 0.60). Although single agent palliative therapy may be considered for PS 2 patients, patients with worse functional status at clinical presentation (ECOG PS ≥3, i.e., bedbound more than 50 % of the day) are often best served with supportive and palliative care.
Patients infected with HIV
In the era of highly active antiretroviral therapies (HAART), the life expectancy of persons with HIV infection has dramatically improved. Although sharp declines have been observed in incidence of malignancies associated with severe immunosuppression (i.e., Kaposi sarcoma, non-Hodgkin's lymphoma, and cervical carcinomatermed AIDS-defining cancers), the prevalence of other malignancies (i.e., the non-AIDS-defining cancers) has concomitantly increased due to aging [34] .
Several epidemiological studies have additionally noted a threefold excess of HNSCC prevalence in HIV-positive populations [34, 35] . Although the known association with oncogenic human papillomavirus (HPV) with oropharyngeal HNSCC has led some to speculate viral co-infection as an explanation for the increased risk of HNSCC in HIV-positive populations, preliminary data from HNSCC specimens of these patients have not clearly supported this hypothesis [36] . Concerns of using systemic therapies for this population include risks of immunosuppression and increased toxicity; however, limited evidence suggests that appropriately selected patients can tolerate organ-preserving therapy [37, 38] . Evidence-based guidelines are lacking to guide appropriate management of this patient population frequently excluded from participation in cancer clinical trials [39, 40] .
Discussion
There is no doubt that chemotherapy and biological therapies have important roles in the management of patients with HNSCC-including radiosensitization as well as systemic effects. The MACH-NC demonstrated a 6.5 % absolute survival benefit associated with the concurrent addition of chemotherapy with radiotherapy regimens [2] , which though significant, leaves much room for improvement. Thus, in the absence of major improvements in survival, therapy-associated toxicities and patient-related factors as well as known risk-benefit ratios must be carefully considered in selecting optimal treatment approaches. Understanding the varied toxicities associated with combined therapy provides even more reason to have such patients treated by teams that have experience with such treatments, including an experienced medical oncologist.
Cetuximab, with known systemic and radiosensitizing effects, is the only approved biological agent for HNSCC patients and has a markedly different toxicity profile compared to cytotoxic agents. Although the toxicities of cetuximab are generally manageable, severe toxicities have been noted with the agent (e.g., hypomagnesemia, rare hypersensitivity reactions, and others including interstitial pneumonitis and cardiovascular toxicities). Given the negative results from the RTOG 0522 trial, cetuximab should not be combined with cisplatin-based chemoradiation regimens [41] , and its use in combination with other chemoradiotherapy regimens must be in the context of clinical trials.
Given its generally favorable toxicity profile, cetuximab has often been advocated as an alternative for patients who may not otherwise be candidates for chemotherapy. However, subset analyses of the study resulting in its approval indication have not demonstrated survival benefit in patients 65 years of age and older and in patients with impaired PS [27] , and controlled studies about tolerance of bioradiotherapy in non-trial patients that are frequently seen in daily practice are lacking. The same is true for the recurrent/metastatic disease setting, where most data on the tolerance of cetuximab in combination with chemotherapy were obtained in patients with ECOG PS of 0 and 1 [42] . However, as a single agent, tolerance is generally acceptable, and most trials using the agent in HNSCC patients with platinum-refractory disease with a WHO PS of 60 % or more (thus including patients with ECOG PS 2), have shown minimal side effects [43] . Persons with incurable malignancy and very poor functional status (ECOG PS 3 or worse) may best be served with supportive and palliative care, since systemic therapy in this setting has unproven benefit.
It is important to consider that radiotherapy alone is effective and a curative-intent treatment modality for HNSCC offering organ preservation, or, in the case of previously resected disease, improved locoregional control and survival outcomes. Thus, most patients with locoregionally advanced disease who either decline concurrent systemic therapy or are deemed to be poor candidates for it can still receive and benefit from radiotherapy. The effectiveness of radiotherapy can be further improved with altered fractionation regimens [3, 4] , particularly for patients with good functional status.
It is also important to note that the above considerations are all clinical in nature, with risk-benefit analyses obtained via individual clinical trials and published meta-analyses; for optimal judgment on how intensive a patient's treatment regimen should be, identification of novel prognostic and predictive biomarkers will be of critical importance.
The identification of oncogenic HPV infection in a subset of oropharyngeal cancers associated with improved patient prognosis has resulted in several prospective investigations testing altered deintensification therapy plans based on this favorable biomarker. As previously untreated HPV-associated disease is remarkably chemosensitive and radiosensitive [44] , the respective roles of chemotherapy and radiotherapy as well as the use of novel surgical options [45] in treatment deintensification need to be further explored in carefully designed prospective trials. In contrast, HPV-negative HNSCC is associated with remarkably poor prognosis despite current therapies, and continued therapeutic intensification efforts under investigation will need to be tempered by patient tolerance.
Conclusions
The care for patients with HNSCC has always been a trade-off between maximizing curative potential while minimizing therapy-related morbidity, and the stepwise advances in multidisciplinary care resulting in current standard therapeutic approaches that have resulted from decades of clinical research. Advances in supportive care, chemotherapy, biological therapy and in radiotherapy derived from this research have permitted increasingly challenging treatment regimens with goals of treatment intensification, to the point where deintensification can today be considered for patients with HPV-associated disease. However, the negative trial data from several recent randomized studies must provide important pause against accepting novel intensification (or deintensification) approaches without rigorous evaluation [9, 28] . The clinical situations discussed in this editorial whereby the use of systemic therapy is not recommended highlight areas for further investigation.
Given the paucity of data available for common populations encountered in practice, comparative effectiveness research and prospectively conducted clinical trials are urgently needed for HNSCC in the elderly and in patients with poor organ function. Patients with HIV infection are also under-represented in HNSCC trials and this population warrants prospective research, either in specific trials or as a formal stratification variable in existing randomized studies. Despite the known advances in the management of HNSCC afforded by systemic therapies, a number of important clinical questions remain for specific clinical settings and patient populations; these questions can only be addressed by supporting and accruing patients to well-designed existing and future clinical trials for this disease.
